D. Mitra

发表

All-Cause Health Care Charges among Managed Care Patients with Constipation and Comorbid Irritable Bowel Syndrome

D. Mitra, K. Davis, R. Baran, 2011, Postgraduate medicine.

Treatment patterns and clinical outcomes among patients receiving palbociclib in combination with an aromatase inhibitor or fulvestrant for HR+/HER2-negative advanced/metastatic breast cancer in real-world settings in the US: Results from the IRIS study.

D. Mitra, G. Milligan, S. Iyer, 2019, Breast.

Real-World Treatment Patterns and Clinical Effectiveness of Palbociclib Plus an Aromatase Inhibitor as First-Line Therapy in Advanced/Metastatic Breast Cancer: Analysis from the US Syapse Learning Health Network

D. Mitra, A. Brufsky, Chenan Zhang, 2022, Current oncology.

Patient-reported Quality of Life and Treatment Satisfaction in Patients With HR+/HER2- Advanced/Metastatic Breast Cancer.

D. Mitra, S. Iyer, J. de Courcy, 2017, Clinical therapeutics.

Patient characteristics and treatment patterns in chronic myeloid leukemia: evidence from a multi-country retrospective medical record chart review study

S. Candrilli, D. Mitra, P. Trask, 2012, International Journal of Hematology.

The economic impact of poor sample quality in clinical chemistry laboratories: results from a global survey

D. Mitra, V. Khangulov, S. Church, 2017, Annals of clinical biochemistry.

PIN39 INPATIENT COSTS AND OUTCOMES ASSOCIATED WITH HEPATITIS C, HUMAN IMMUNODEFICIENCY VIRUS, AND CO-INFECTION WITH BOTH IN THE UNITED STATES

D. Mitra, S. Candrilli, 2008 .

Localization and Thyroid Hormone Influenced Expression of Collagen II in Ovarian Tissue

D. Mitra, S. Saha, Pamela Ghosh, 2007, Cellular Physiology and Biochemistry.

Patterns and prognostic indicators of response to CML treatment in a multi-country medical record review study

S. Candrilli, D. Mitra, P. Trask, 2012, International Journal of Hematology.

Real-World Palbociclib Use in HR+/HER2− Advanced Breast Cancer in Canada: The IRIS Study

D. Mitra, G. Milligan, G. Taylor‐Stokes, 2021, Current oncology.

Health and Economic Consequences of Fragile X Syndrome for Caregivers

D. Bailey, D. Mitra, E. Bishop, 2012, Journal of developmental and behavioral pediatrics : JDBP.

D. Mitra, Jifang Zhou, G. Calip, 2022, Journal of patient experience.

Reply to L. Reale et al. “More and better should be done to guarantee evidence-based management of ADHD in children across Europe”

V. Harpin, D. Mitra, J. Quintero, 2014, European Journal of Pediatrics.

Systematic review and network meta-analysis comparing palbociclib with chemotherapy agents for the treatment of postmenopausal women with HR-positive and HER2-negative advanced/metastatic breast cancer

Chris Cameron, Abhishek Varu, D. Mitra, 2017, Breast Cancer Research and Treatment.

Treatment satisfaction in women receiving palbociclib combination therapies for advanced/metastatic breast cancer.

D. Mitra, S. Iyer, D. Mcsorley, 2019, Future oncology.

Health care resource utilization and costs associated with nonfatal major adverse cardiovascular events.

Jennifer S. Korsnes, D. Mitra, K. Davis, 2015, Journal of managed care & specialty pharmacy.

Symptom burden and splenomegaly in patients with myelofibrosis in the United States: a retrospective medical record review

D. Mitra, N. Sarlis, T. Mughal, 2013, Cancer medicine.

Association between oral 5-ASA adherence and health care utilization and costs among patients with active ulcerative colitis

P. Hodgkins, D. Mitra, K. Davis, 2012, BMC Gastroenterology.

J. Piercy, C. Criscitiello, S. Kurosky, 2021, Clinical therapeutics.

Direct economic burden of high-risk and metastatic melanoma in the elderly

J. Wolchok, D. Mitra, K. Davis, 2009 .

Comparison of palbociclib in combination with letrozole or fulvestrant with endocrine therapies for advanced/metastatic breast cancer: network meta-analysis

D. Mitra, S. Iyer, J. Kaye, 2017, Current medical research and opinion.

Real-world patterns of systemic therapy utilization in high risk and metastatic melanoma: evidence from the SEER-Medicare linked database

U. Iloeje, D. Mitra, K. Davis, 2008 .

PCN96 REAL WORLD TREATMENT PATTERNS IN HIGH RISK OR METASTATIC MELANOMA: EVIDENCE FROM THE SEER-MEDICARE LINKED DATABASE

U. Iloeje, D. Mitra, K. Davis, 2008 .

Does recall period matter? Comparing PROMIS® physical function with no recall, 24-hr recall, and 7-day recall

J. Beaumont, D. Cella, D. Eek, 2019, Quality of Life Research.

Management of ADHD in children across Europe: patient demographics, physician characteristics and treatment patterns

V. Harpin, D. Mitra, J. Quintero, 2013, European Journal of Pediatrics.

Direct Economic Burden of Chronic Hepatitis C Virus in a United States Managed Care Population

D. Mitra, K. Davis, V. Rustgi, 2011, Journal of clinical gastroenterology.

Population-based recurrence rates among older women with HR-positive, HER2-negative early breast cancer: Clinical risk factors, frailty status, and differences by race

D. Mitra, Jifang Zhou, G. Calip, 2021, Breast.

Real-world treatment patterns and clinical outcomes in patients receiving palbociclib combinations for HR+/HER2- advanced/metastatic breast cancer in Japan: Results from the IRIS study.

Kieran Hart, D. Mitra, G. Milligan, 2022, Cancer treatment and research communications.

Abstract OT3-03-01: MADELINE: A prospective observational study of mobile app-based patient reported outcomes in advanced breast cancer

D. Mitra, A. Zelnak, J. Kaye, 2017 .

Cost and cost-effectiveness of the COMBINE study in alcohol-dependent patients.

D. Couper, G. Zarkin, Arnie P Aldridge, 2008, Archives of general psychiatry.

CDK4/6 inhibitors in HR+/HER2- advanced/metastatic breast cancer: a systematic literature review of real-world evidence studies.

N. Harbeck, D. Mitra, C. Cameron, 2021, Future Oncology.

PCN28 CYCLIN-DEPENDENT KINASE 4/6 INHIBITORS (CDK4/6I) IN HORMONE RECEPTOR-POSITIVE/HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-NEGATIVE (HR+/HER2-) ADVANCED/METASTATIC BREAST CANCER (A/MBC): A SYSTEMATIC LITERATURE REVIEW OF REAL-WORLD EVIDENCE (RWE) STUDIES

N. Harbeck, D. Mitra, C. Cameron, 2020 .

Abstract P6-18-21: Real world treatment patterns and outcomes of patients receiving palbociclib plus fulvestrant in the United States: Sub-groups analysis based on age, performance status and sites of metastases

D. Mitra, G. Milligan, S. Iyer, 2019, Poster Session Abstracts.

Real-World Treatment Patterns and Clinical Outcomes Associated With Palbociclib Combination Therapy: A Multinational, Pooled Analysis From the Ibrance Real World Insights Study.

D. Mitra, G. Milligan, E. Law, 2022, Clinical therapeutics.

Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b–3 trial

J. Shapiro, D. Mitra, B. King, 2023, The Lancet.

Real-world treatment of patients with palbociclib for HR+/HER2-advanced/metastatic breast cancer: the Europe IRIS study.

Kieran Hart, D. Mitra, G. Milligan, 2021, Future oncology.

The Effect of Screening and Brief Intervention for Risky Drinking on Health Care Utilization in Managed Care Organizations

G. Zarkin, D. Mitra, K. Davis, 2007, Medical care.

Treatment Patterns and Outcomes Associated With Palbociclib Plus Letrozole for Postmenopausal Women With HR-/HER2- Advanced Breast Cancer Enrolled in an Expanded Access Program.

V. Stearns, D. Mitra, K. Davis, 2019, Clinical breast cancer.

Treatment Patterns and Outcomes of Patients With Metastatic ER+/HER‐2− Breast Cancer: A Multicountry Retrospective Medical Record Review

S. Kurosky, D. Mitra, J. Kaye, 2017, Clinical breast cancer.

Patient Reported Health Utility in HR+/HER2- Advanced/Metastatic Breast Cancer

D. Mitra, S. Iyer, R. Wood, 2016 .

Cost methodology of COMBINE.

D. Kivlahan, G. Zarkin, D. Mitra, 2005, Journal of studies on alcohol. Supplement.

A prospective observational study of patient-reported functioning and quality of life in advanced and metastatic breast cancer utilizing a novel mobile application

D. Mitra, J. Hargis, R. Mahtani, 2021, Breast Cancer Research and Treatment.

Patient-reported pain severity, pain interference and health status in HR+/HER2− advanced/metastatic breast cancer

D. Mitra, S. Iyer, J. de Courcy, 2017, ESMO Open.

Real-World Treatment Patterns and Clinical Outcomes in Patients Receiving Palbociclib for Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced or Metastatic Breast Cancer in Argentina: The IRIS Study

D. Mitra, G. Milligan, S. Iyer, 2019, Journal of global oncology.

Treatment patterns and adherence among patients with chronic hepatitis C virus in a US managed care population.

D. Mitra, K. Davis, V. Rustgi, 2010, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Treatment patterns and clinical outcomes with palbociclib-based therapy received in US community oncology practices.

N. Hu, M. Fisher, D. Mitra, 2020, Future oncology.

Measuring economic outcomes of alcohol treatment using the Economic Form 90.

D. Couper, W. Miller, D. Kivlahan, 2007, Journal of Studies on Alcohol and Drugs.

Matching-adjusted indirect comparison of palbociclib versus ribociclib and abemaciclib in hormone receptor-positive/HER2-negative advanced breast cancer.

H. Rugo, D. Mitra, C. Cameron, 2021, Journal of comparative effectiveness research.

Abstract P5-21-24: Retrospective assessment of treatment patterns and outcomes associated with palbociclib plus letrozole for postmenopausal women with HR+/HER2– advanced breast cancer enrolled in an early access program

V. Stearns, D. Mitra, A. Brufsky, 2018 .

Impact of time to distant recurrence on breast cancer-specific mortality in hormone receptor-positive breast cancer

D. Mitra, Jifang Zhou, G. Calip, 2022, Cancer Causes and Control.